Ivonescimab with cadonilimab or ipilimumab for advanced clear cell kidney cancer
Tests ivonescimab, alone or with other drugs, in adults with advanced clear cell kidney cancer.
Plain-language title generated from the registry record
Registry title: A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- BeijingBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Summit Therapeutics
- Trial code
- NCT07877194
- Record updated
- 16 October 2026
- Original description
This study aims to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC).Read full original descriptionShow less
A Phase II Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab in the Treatment of Advanced Renal Cancer
This study aims to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
Inclusion: Able to understand and voluntarily sign a written informed consent form, which must be signed prior to the performance of the designated study procedures required by the study; Age ≥ 18 years both male and female; Karnofsky Performance Status Score (KPS) ≥ 70%; Expected survival ≥ 6 months; According to RECIST v1.1, there is at least one measurable lesion that is suitable for repeated and accurate measurements; Histologically or cytologically, pathologically confirmed renal cancer with a clear cell carcinoma component (ccRCC); Locally advanced or metastatic RCC not amenable to curative surgery or radiotherapy; Adequate organ function.
Exclusion: Previous anti-tumor therapy toxicity has not been resolved; Have other malignancies within 5 years prior to enrollment; Locally advanced disease that is resectable or suitable for local therapy with curative intent; Known presence of active pulmonary tuberculosis and active syphilis infection; Histologically or cytologically confirmed renal non-clear cell carcinoma (nccRCC); Presence of active central nervous system (CNS) metastases; Other reasons for ineligibility as evaluated by investigator.